Today: 20 May 2026
Intel stock bounces in premarket after 6% slide — here’s what traders watch next
11 February 2026
2 mins read

Intel stock bounces in premarket after 6% slide — here’s what traders watch next

New York, Feb 11, 2026, 07:02 EST — Premarket

  • Intel clawed back roughly 0.5% in premarket trading, following a steep 6.2% slide the day before.
  • Investors pulled back from tech on Tuesday, unloading shares before U.S. payrolls data hits.
  • Attention is turning to upcoming macro data, while Intel gears up for its next round of updates at the Mobile World Congress in March.

Intel Corp shares ticked 0.5% higher before the bell Wednesday, changing hands at $47.38. On Tuesday, the stock had dropped 6.19% to close at $47.13, after opening at $50.41 and ranging from $46.77 to $50.54. Roughly 99.83 million shares traded, right around its three-month average.

Tech stocks lost ground as some investors stepped back ahead of the U.S. January payrolls report expected later Wednesday; December retail sales, meanwhile, were flat, catching some by surprise. The Nasdaq dropped 0.59% on Tuesday, the S&P 500 lost 0.33%, but the Dow still edged out another record close. “Nobody wants to get too far above their risk budget,” said Mark Luschini, chief investment strategist at Janney Montgomery Scott. Reuters

Intel remains a high-stakes turnaround story with CEO Lip-Bu Tan at the helm, but nagging issues—supply bottlenecks and manufacturing hiccups—have put the company on a short leash with investors. Last month, Reuters flagged Intel’s ongoing trouble keeping up with demand for server chips powering AI data centers, and pointed to yield snags with new production tech. Tan acknowledged 18A yields are “still below what I want them to be.” Michael Schulman, chief investment officer at Running Point Capital, summed up the situation: Intel is “supply-constrained rather than demand-constrained.” Reuters

Intel plans to use this year’s Mobile World Congress in Barcelona to put a spotlight on AI inference — that is, deploying trained models on real-time data right inside mobile networks. The pitch: an “open” platform designed to drive up efficiency and trim operator costs. The chipmaker is pointing to network and edge upgrades that don’t require expensive “rip-and-replace” overhauls, and has flagged both its booth location and a March 3 talk from Cristina Rodriguez, who heads up Intel’s Network & Edge Group as VP and GM. Newsroom

Investors want more than talk — they’ll be looking for signed deals, design wins, and proof that telecom and edge projects are moving from demo stage to actual revenue. Intel, for its part, faces the ongoing challenge: Can it keep margins steady and deliver enough chips where demand exists, while avoiding a repeat of factory stumbles?

Chip names showed little consensus Wednesday morning. Nvidia lost about 0.7%, with AMD off 1.1% early on, both weighing on the sector. Intel, by comparison, managed to find some footing.

Macro risk looms in the short run. If jobs data comes in hot, those rate worries may flare up again—and growth stocks that react to yields have shown little hesitation to adjust fast when bonds shift.

For Intel, fresh chatter around supply constraints, hiccups in production timelines, or lagging customer uptake tends to hit a stock that’s already been see-sawing with every bit of news on its execution. Tuesday’s slide under $50 left a mark on the chart—a slight premarket bounce barely registers against that backdrop.

Traders are set to watch the stock’s action when the opening bell rings Wednesday, after a steep drop. Attention will also be on whether buyers step in, especially as the payrolls report lands and shifts rate expectations.

Looking past the numbers, Intel’s next scheduled event is Mobile World Congress in Barcelona, set for March 2–5. Investors will be watching closely, scanning for any fresh clues that the company’s network-and-edge strategy is actually generating orders.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
QVC Group stock (QVCGA) plunges on creditor-talks report as bankruptcy risk comes into view
Previous Story

QVC Group stock (QVCGA) plunges on creditor-talks report as bankruptcy risk comes into view

Accenture stock drops as CEO share-sale filing and $1.4 billion contract protest hit tape
Next Story

Accenture stock drops as CEO share-sale filing and $1.4 billion contract protest hit tape

Go toTop